title: Strategies and challenges for the next generation of therapeutic antibodies.
abstract: Antibodies and related products are the fastest growing class of therapeutic agents. By analysing the regulatory approvals of IgG-based biotherapeutic agents in the past 10 years, we can gain insights into the successful strategies used by pharmaceutical companies so far to bring innovative drugs to the market. Many challenges will have to be faced in the next decade to bring more efficient and affordable antibody-based drugs to the clinic. Here, we discuss strategies to select the best therapeutic antigen targets, to optimize the structure of IgG antibodies and to design related or new structures with additional functions.
authors.affiliation: Centre d'Immunologie Pierre Fabre (CIPF), 5 Avenue Napoléon III, F74160, Saint-Julien-en-Genevois, France. alain.beck@pierre-fabre.com
authors.forename: Alain
authors.initials: A
authors.lastname: Beck
authors.forename: Thierry
authors.initials: T
authors.lastname: Wurch
authors.forename: Christian
authors.initials: C
authors.lastname: Bailly
authors.forename: Nathalie
authors.initials: N
authors.lastname: Corvaia
mesh_terms: D000818:Animals; D018033:Antibodies, Bispecific / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015415:Biomarkers; D016207:Cytokines / Q000037:antagonists & inhibitors; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007074:Immunoglobulin G / Q000737:chemistry; D015202:Protein Engineering
chemical_list: D018033:Antibodies, Bispecific; D000911:Antibodies, Monoclonal; D015415:Biomarkers; D016207:Cytokines; D018796:Immunoconjugates; D007074:Immunoglobulin G